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Abstract
Retinoic acid (RA) has paradoxical effects on cancer cells: promoting cell death, differentiation and cell cycle arrest, or cell
survival and proliferation. Arachidonic acid (AA) release occurs in response to RA treatment and, therefore, AA and its
downstream metabolites may be involved in cell survival signalling. To test this, we inhibited phospholipase A2-mediated
AA release, cyclooxygenases and lipoxygenases with small-molecule inhibitors to determine if this would sensitise cells to
cell death after RA treatment. The data suggest that, in response to RA, phospholipase A2-mediated release of AA and
subsequent metabolism by lipoxygenases is important for cell survival. Evidence from gene expression reporter assays and
PPARd knockdown suggests that lipoxygenase metabolites activate PPARd. The involvement of PPARd in cell survival is
supported by results of experiments with the PPARd inhibitor GSK0660 and siRNA-mediated knockdown. Quantitative
reverse transcriptase PCR studies demonstrated that inhibition of 5-lipoxygenase after RA treatment resulted in a strong up-
regulation of mRNA for PPARd2, a putative inhibitory PPARd isoform. Over-expression of PPARd2 using a tetracycline-
inducible system in neuroblastoma cells reduced proliferation and induced cell death. These data provide evidence linking
lipoxygenases and PPARd in a cell survival-signalling mechanism and suggest new drug-development targets for malignant
and hyper-proliferative diseases.
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Introduction
Retinoic acid (RA) is a biologically-active vitamin A metabolite
used in the treatment of neuroblastoma and acute promyelocytic
leukaemia [1]. In vitro, RA induces growth arrest, down-regulation
of MYCN expression [2] and differentiation in neuroblastoma
cells [3]. Paradoxically, RA can promote increased proliferation
and cell survival in certain cell types [4], [5]. Like other anticancer
agents such as cisplatin and tamoxifen, RA induces arachidonic
acid (AA) release in cancer cells [6–9], and this may promote cell
survival under conditions of cell stress. Furthermore, celecoxib, a
non-steroidal anti-inflammatory drug and cyclooxygenase (COX2)
inhibitor which inhibits the metabolism of AA, potentiates the
effects of both RA and cytotoxic drugs in neuroblastoma cells [10–
12].
RA has been reported to activate Peroxisome Proliferator-
Activated Receptor (PPAR) d, a ligand-activated transcription
factor controlling cell growth and proliferation and important for
cell survival [13]. RA is thought to be transported into the nucleus
by cellular retinoic acid binding proteins (CRABP) or fatty acid
binding protein 5 (FABP5) and it has been proposed that CRABP2
mediates RA transfer to RA receptors (RAR) to promote
differentiation or apoptosis, whereas FABP5 mediates RA transfer
to PPARd heterodimers promoting cell survival [14]. Evidence for
the direct activation of PPARd by RA is controversial, with later
studies suggesting that RA does not directly bind to PPARd or
activate PPAR target genes [15–17]. Nevertheless, there may well
be interactions between RAR and PPARd signalling pathways in
development; for example, it has recently been suggested that
neural differentiation is regulated by an RAR-mediated commit-
ment phase followed by the promotion of differentiation via a
PPARd-mediated up-regulation of PDK1 [18]. The role of
PPARd in cell signalling is likely to be complex; five different
mRNA isoforms of PPARd have been described, with PPARd1
and PPARd2 being the most abundantly expressed in human
tissues; although PPARd2 has been suggested to represent an
inhibitory isoform, a translational product has yet to be identified
[18].
Given the activity of celecoxib in inducing cell death in
combination with RA, it is possible that AA metabolites are
important in promoting cell survival and may interact with RAR-
and/or PPARd-mediated signalling. To test this hypothesis and
elucidate the mechanism of interaction between RA and celecoxib,
we investigated the effect of inhibiting AA release, cyclooxygenases
and lipooxygenases on the survival of neuroblastoma cells after RA
treatment. The data suggest that 5-lipoxygenase (5-LO) inhibition
sensitises neuroblastoma cells to apoptosis and that celecoxib
promotes RA-induced neuroblastoma cell death in vitro through
the inhibition of 5-LO. Further experiments to clarify the potential
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role of 5-LO suggest that the 5-LO product 5-oxo-eicosatetraenoic
acid (5-oxo-ETE) mediates cell survival through PPARd.
Materials and Methods
Established Cell Lines and Culture Conditions
SH-SY5Y [19], NGP [20] and NB69 [21] neuroblastoma cells
were grown in 1:1 DMEM/F12 (Sigma-Aldrich, Poole, UK)
supplemented with 10% FBS (Invitrogen, Paisley, UK) at 37uC in
5% CO2. SH-SY5Y
tet12 cells [22] were grown in DMEM/F12 1:1
10% FBS, supplemented with blasticidin (5 mg/ml; Invitrogen).
Chemicals
All-trans RA (ATRA), AACOCF3, GSK0660, MK886 and
Prostaglandin E2 (PGE2) were from Sigma-Aldrich, PD-146176
from Enzo Life Sciences (Farmindale, NY), celecoxib from Pfizer
(NY), baicalein, 5-oxo-ETE and leukotriene A4 (LTA4) methyl
ester were from Cayman Chemicals (Ann Arbor, MI). LTA4 is
stable at 4uC for 24 h; therefore, we used LTA4 methyl ester and
performed hydrolysis according to manufacturer’s instructions
immediately prior to experiments to convert the stable LTA4
methyl ester into LTA4. L165-041 was from Tocris Bioscience
(Ellisville, MO).
Flow Cytometry
Adherent and non-adherent cells were fixed in 70% ethanol,
30% PBS, then spun down and resuspended in PBS containing
40 mg/ml propidium iodide and 100 mg/ml RNAse A. Fluores-
cence from excitation at 488 nm with a 15-mW argon laser was
monitored at 585621 nm using a FACScan flow cytometer with
CellQuest software (Becton Dickinson, San Jose, CA). Events were
counted using a doublet-discriminator parameter to exclude
aggregates and a threshold of forward and side scatter was used
to exclude debris. Cell-cycle and cell-death analysis was carried
out on the same samples using WinMDI (version 2.8, TSRI, La
Jolla, CA).
PPARd siRNA
10 nM PPARd SMART-pool siRNA (Dharmacon, Lafayette,
CO) was complexed with lipofectamine in OptiMEM (Invitrogen),
according to the manufacturer’s instructions. Control siRNAs
were a universal scrambled negative control (SCR) (Qiagen,
Ontario, Canada). Cells were transfected with siRNA for 24 h
prior to treatment with ATRA. Levels of apoptosis were higher in
SH-SY5Y cells treated with siRNA (SCR or PPARd), therefore,
for assessing the effects of knockdown on ATRA-induced apoptosis
the data were normalised to the zero-ATRA control for each
siRNA.
PPARd Reporter Assay
Cells were transfected with 667 ng of PPAR response element
(PPRE) construct, negative or positive control plasmids from the
PPRE cignal dual luciferase reporter assay kit (SAbiosciences,
Frederick, MD) using lipofectamine. 24 h after transfection, cells
were treated with drug combinations for 2 h. Cells were harvested
and transferred to a 96-well plate; 50 ml of Stop and Glow solution
(Promega, Madison, WI) was added to each well and luminescence
measured on a LB96V Microplate Luminometer (EG & G
Berthold, Bad Wildbad, Germany).
Establishment of a Stable Inducible PPARd2 Over-
expression System in SH-SY5Y Cells
Human PPARd, mRNA transcript variant 2 cDNA in pOTB7
(IOH5357, Invitrogen) was subcloned into BamH1 and Xho1 sites
of pcDNA4/TO (Invitrogen). The construct was transfected into
SH-SY5Ytet12 cells expressing the TET repressor [22]. After
Figure 1. Inhibition of AA metabolism promotes RA mediated
cell death. All graphs show data for SH-SY5Y cells. Apoptosis was
measured after 24 h of treatment using flow cytometry in (A) and (B).
The apoptotic fraction was determined as the sub-G1 peak. (A)
Apoptosis of cells treated with ATRA alone (N, solid line) or ATRA in
combination with 10 mM of the PLA2 inhibitor AACOCF3 (%, dashed
line). Levels of apoptosis were significantly higher in the SHSY5Y cells
treated with a combination of ATRA and AACOCF3 (ANOVA, P,0.001).
(B) Apoptosis of cells treated with ATRA alone (N, solid line) or ATRA in
combination with 22 mM celecoxib (%, dashed line). The interaction P-
value for ATRA and celecoxib was P = 0.03 (ANOVA). For apoptosis
experiments there were three technical replicates for each of three dose
response curve experiments. Viability results for the corresponding
experiments are summarised in Table 1 with additional viability data for
NGP and NB89 cells in Table S1. (C) Western blot for cleaved caspase-3,
6 h after treatment with ATRA or ATRA with 22 mM celecoxib, size
markers from ladder are shown; the full blot is shown in Figure S3.
doi:10.1371/journal.pone.0068859.g001
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selection using zeocin (250 mg/ml) and blasticidin (5 mg/ml), a
mixed population of cells was used for experiments (SH-
SY5Ytet12PPARd2). Addition of 1 mg/ml doxycycline to the
medium induced PPARd2 expression (referred to as PPARd2+ve).
Cells grown without doxycycline are referred to as PPARd2-ve. To
confirm results, transient transfections were carried out using the
pcDNA4/TO PPARd2 construct and native SH-SY5Y cells.
RNA Extraction and Quantitative Reverse Transcriptase
PCR for PPARd
RNA was extracted using the RNeasy mini kit (Qiagen) and
DNAse-treated using the DNA-free kit (Qiagen). 1 mg of RNA was
reverse transcribed using a high-capacity reverse transcription kit.
Levels of PPARd1 and PPARd2 were measured using Taqman
assays (PPARd1: Hs00606407_m1 and PPARd2 Hs02516538_s1)
and normalised to endogenous GAPDH (Hs99999905_m1).
Quantitative reverse transcriptase (qRT-PCR) was carried out
using the relative quantification protocol on an ABI Prism
7900HT and analysed using SDS software (Applied Biosystems,
Foster City, CA).
XTT Viability and Cell Growth Assays
The XTT assay (Roche Diagnostics, Basel, Switzerland) was
used as previously described [23]. The experimental conditions
were based on standard calibration curves to establish the
appropriate initial plating density. For viability dose-response
curves, cells were seeded at 2 x104 per well into 96-well microtiter
plates (Corning, Amsterdam, Netherlands) and left to adhere
overnight; inhibitors and ATRA were diluted in OptiMEM to the
appropriate concentrations. For growth curves, cells were plated at
56103 per well, and XTT absorbance was measured on 3
consecutive days. Treated cells were incubated for 24 h before
XTT solution was added; plates were read at 480 nm 4 h after
XTT addition.
Western Blotting
Cells were lysed in buffer containing protease inhibitors (Roche
Diagnostic, Mannheim, Germany). Protein concentrations were
measured using Bradford reagent (Pierce, Rockford, IL) and equal
quantities separated by SDS-PAGE, transferred to nylon mem-
branes (Bio-Rad, Hertfordshire, UK) and probed with antibodies
against COX2 (Santa Cruz Biotechnology Inc, Santa Cruz, CA),
cleaved caspase-3 (Cell Signalling Technologies, Danvers, MA)
and b-actin (Sigma-Aldrich). Anti-mouse IgG conjugated with
horseradish-peroxidase (Upstate, Billerica, MA, USA) was used as
secondary antibody and enhanced chemiluminescence Western
blotting detection reagent (GE Healthcare, Buckinghamshire, UK)
was used for detection.
Statistics
Graphs were plotted using Sigmaplot 11.0 (San Jose, CA). Dose-
response curves were fitted using the non-linear mixed-effects
model fit in the nlme package [24] in R [25]. For other
experiments, univariate ANOVA (with contrasts) was performed
in SPSS Version 17 (Chicago, IL), and t-tests (unpaired) and linear
mixed-effects models (nlme package [24]) were performed using R.
Where relevant, combination indices (CI) were calculated using
Calcusyn (Biosoft, Cambridge, UK). CI.1 indicates an antago-
nistic interaction between two drugs and a CI,1 indicates
synergy. All errors are expressed as standard error of the mean
(SEM). For clinical data, Wilcoxon test was used to assess
differential expression in MYCN-amplified (all stages) versus non-
MYCN-amplified (all stages). For Kaplan-Meier survival analysis
the best cut off between low and high PPARd1 expression was
determined as the 1st quartile. The log-rank test was used to test
whether the two survival curves are different.
Results
Inhibition of AA Metabolism Promotes RA-mediated Cell
Death
Several studies have shown that RA promotes AA release from
nuclear membranes [6], [7]. To determine if AA release is
important in survival of cells treated with all-trans RA (ATRA), we
inhibited phospholipase A2 (PLA2) using 10 mM AACOCF3 prior
to ATRA treatment (Figure 1A & Table 1); this concentration of
AACOCF3 has been used previously to inhibit AA release in
neuroblastoma cell lines [26]. Flow-cytometry was used to estimate
the proportion of cells within the sub G1 peak as a measure of cell
death in SH-SY5Y cells; the results were confirmed by XTT
viability assays in SH-SY5Y, NGP and NB69 cells. The data
showed that AACOCF3 facilitated ATRA-dose-dependent cell
death in all three neuroblastoma cell lines (Figure 1A; Table 1 and
Table S1). These results suggest that AA is critical for cell survival
after ATRA treatment.
Table 1. Viability of SH-SY5Y neuroblastoma cells treated with ATRA (dose-response) alone or in the presence of AA-signalling
inhibitors.
Drug (concentration) Target Drug alone (% viability)
% viability using drug in
combination with 15 mM
ATRA
IC50 (mM) ATRA in combination
with drug
ATRA (0.5 mM to 15 mM) 95.5362.05* 95.5362.05* 7.8860.002
AACOCF3 (10 mM) PLA2 76.88614.17 0 7.5661.05
Celecoxib (22 mM) COX2/5-LO 89.5466.97 0 4.2762.03
MK886 (1 mM) FLAP (5-LO) 59.7612.7 0 4.961.7
GSK0660 (0.2 mM) PPARd 88.0610.6 0 10.260.3
*ATRA alone: Viability at 15 mM.
SH-SY5Y cells were pre-treated for 2 h with inhibitor (or vehicle control) at the concentrations specified (left column) prior to the addition of ATRA and viability was
measured after 24 h incubation with ATRA in the presence of inhibitor using XTT assays. The % viability of the cells treated with the specified dose of inhibitor alone
(middle right column) is given alongside the IC50 of ATRA and inhibitor together (right column). Unless otherwise stated, the IC50 was calculated from data where 0%
viability resulted from the maximal ATRA concentration. For viability experiments, there were 6 technical replicates for each dose-response curve and each dose-
response curve was performed three times. Results are mean %6SEM.
doi:10.1371/journal.pone.0068859.t001
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AA is a substrate for cycloxygenases and lipoxygenases and is
metabolised to prostaglandins or lipoxins, leukotrienes and
hydroxy-eicosatetraenoic acids [27], [28]. Therefore, we used
small-molecule inhibitors to target cyclooxygenases and lipoxy-
genases in combination with ATRA. Firstly, we treated neuro-
blastoma cells with a sub-lethal dose (22 mM) of celecoxib; in
combination with ATRA, celecoxib synergistically decreased cell
viability in all three cell lines (combination index [CI] = 0.119 for
SH-SY5Y cells with 15 mM ATRA; Table 1 & Table S1).
Apoptosis data revealed that celecoxib in combination with ATRA
increased apoptosis in a dose-dependent manner (Figure 1B).
Elevated levels of apoptosis after 24 h in cells treated with ATRA
and celecoxib were confirmed by substantially-increased caspase-3
cleavage relative to ATRA alone after 6 h of treatment (Figure 1C).
Although cleaved caspase-3 increased in SH-SY5Y cells after
treatment with 10 mM or 15 mM of ATRA for 6 h, at 10 mM
ATRA this was not linked to a detectable increase in apoptosis at
24 h. Thus, caspase-3 cleavage occurred to a greater extent and
with lower concentrations of ATRA in the combination treatment,
and corresponded to significantly higher apoptosis at 24 h.
5-LO Promotes Cell Survival After RA Treatment
As celecoxib is well known as a COX2 inhibitor, we investigated
the role of AA metabolism by COX2 in promoting cell survival
after ATRA treatment and concluded that COX2 was not the
main cell-survival mediator of ATRA in neuroblastoma cells (Text
S1, Figure S1 and Figure S4). Celecoxib also inhibits 5-LO [29]
and 5-LO is expressed in neuroblastoma cell lines [26] and
tumours [30]. To determine if 5-LO inhibition promotes synergy
between celecoxib and ATRA we tested the combination of the 5-
LO inhibitor MK886 and ATRA. To become catalytically active,
5-LO binds the 5-LO activating protein FLAP; MK886 also binds
FLAP and as a consequence inhibits 5-LO activity [31]. In SH-
SY5Y cells, 1 mM MK886 is a sub-lethal dose [22] but apoptosis
increased significantly when combined with increasing doses of
ATRA (Figure 2A). MK886 in combination with ATRA
effectively reduced survival in all three neuroblastoma cell lines
(Table 1 and Table S1). We assessed the contribution of AA
metabolism by lipoxygenases 12-LO and 15-LO to cell-survival
signalling and concluded that 5-LO inhibition was the most
effective strategy for promoting cell death in combination with
ATRA (Text S2, Table S2).
5-LO oxidises AA to both LTA4 and 5S-hydroperoxy-
6,8,11,14-eicosatetraenoic acid; the latter is rapidly reduced and
then oxidised by NADP+-dependent 5-hydroxyeicosanoid dehy-
drogenase (5HEDH) activity to 5-oxo-ETE [32]. If 5-LO
metabolites promote cell survival after ATRA treatment, we
would predict that pre-incubation with 5-oxo-ETE or LTA4
would rescue cells from ATRA and 5-LO inhibition. In
experiments to test this, 5-oxo-ETE partially rescued SH-SY5Y
cells from death induced by 22 mM celecoxib and ATRA or 1 mM
MK886 and ATRA (Figure 2B and C). Viability assays confirmed
the apoptosis results: at the maximum dose of ATRA (15 mM), 5-
Figure 2. A 5-LO metabolite promotes cell survival after RA
treatment. All graphs show data for SH-SY5Y cells. Apoptosis was
measured by flow cytometry as the size of the sub-G1 peak. (A)
Apoptosis of cells treated with increasing doses of ATRA alone (N, solid
line) or with 1 mM MK886 (%, dashed line). The interaction P-value for
MK886 and ATRA was,0.001 (ANOVA). Data for MK886 alone are in
Table 1. (B) Apoptosis of cells treated with increasing doses of ATRA in
combination with 22 mM celecoxib (%, solid line) or after pre-treatment
with 0.1 mM 5-oxo-ETE prior to increasing doses of ATRA in combination
with 22 mM celecoxib (&, dashed line). The interaction between 5-oxo-
ETE and celecoxib/ATRA was significant, P = 0.001 (ANOVA). (C)
Apoptosis of cells treated with increasing doses of ATRA in combination
with 1 mM MK886 (%, solid line) or after pre-treatment with 0.1 mM 5-
oxo-ETE prior to increasing doses of ATRA in combination with 1 mM
MK886 (&, dashed line). The interaction between 5-oxo-ETE and
MK886/ATRA was significant, P = 0.005 (ANOVA). (D) Rescue, expressed
as % viability, of cells treated with 15 mM ATRA with 22 mM celecoxib
(light grey bars) or ATRA with 1 mM MK886 (dark grey bars) by pre-
treatment with increasing doses (0, 2 nM, 10 nM or 0.1 mM) 5-oxo-ETE.
All error bars are6SEM.
doi:10.1371/journal.pone.0068859.g002
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oxo-ETE increased viability from 5.6%62.4 to 42.6%67.06 with
the combination of ATRA and celecoxib (Table 2). A similar effect
was observed with the combination of 1 mM MK886 and 15 mM
ATRA, with viability increasing from 1.3%61.5 to 22.05%66.4
in the presence of 5-oxo-ETE (Table 2). The data show that 5-oxo
ETE affected levels of cell survival at high concentrations of
ATRA (the lower asymptote), and that the effects of 5-oxo-ETE
were dose dependent (Figure 2D). In contrast, 0.1 mM LTA4 did
not rescue SH-SY5Y cells from celecoxib or MK886 in
combination with ATRA (Table 2). We interpret these results to
suggest that metabolism of AA by 5-LO promotes cell survival in
neuroblastoma cells.
PPARd Activation by 5-oxo-ETE is Involved in RA-
mediated Cell Survival Signalling
Previous studies have suggested that PPARd mediates survival
response to ATRA [13], [14]. Assays for PPRE binding activity in
nuclear extracts from SH-SY5Y cells demonstrated that PPARd
was 4.5- to 6-fold more abundant than PPARa or PPARc (Figure
S2A). PPRE activation increased significantly in SH-SY5Y cells
after treatment with 4 or 8 mM ATRA (2.360.4 and 1.660.01 -
fold respectively; Figure 3A). Importantly, 0.1 mM 5-oxo-ETE
increased PPRE activation to similar levels observed with 4 and
8 mM ATRA, suggesting that 5-oxo-ETE is substantially more
potent than ATRA (Figure 3A). Furthermore, treatment with
MK886 reduced PPRE activation in response to ATRA (Figure
S2B). Therefore, these results suggest that PPRE activation in
response to ATRA may be an indirect effect resulting from
stimulation of PPAR by AA metabolites such as 5-oxo-ETE.
PPARd siRNA knock-down in SH-SY5Y cells was used to
determine if PPARd mediates increased PPRE-binding activity
after ATRA treatment. Levels of PPARd1, the full-length PPARd
transcript, and PPARd2 were measured 24 h after treatment with
siRNA (control samples) and 2 h after subsequent treatment with
4 or 10 mM ATRA (Figure 3B). Before ATRA treatment,
PPARd1 mRNA was reduced by 58%; after treatment with
ATRA, PPARd1 mRNA levels remained between 40–60%
compared to the corresponding scrambled (SCR) siRNA control
(Figure 3B). The specificity of the commercially-supplied PPARd
siRNA with respect to the PPARd1 and PPARd2 isoforms is
unknown but there was no significant effect of the PPARd siRNA
on PPARd2 transcript levels (ANOVA, scrambled versus PPAR
siRNA, P= 0.46). There was no significant difference in PPRE
reporter-gene activity between the PPARd and SCR siRNA-
treated controls (Figure 3C) but levels of PPRE reporter activity in
cells treated with 4 or 10 mM ATRA were significantly lower in
the PPARd siRNA-treated cells (Figure 3C).
PPARd Inhibition Promotes Cell Death after ATRA
Treatment
To investigate the role of PPARd in cell survival, PPARd
activity was inhibited prior to ATRA treatment using two different
approaches: a small-molecule PPARd inhibitor, GSK0660, and
siRNA-mediated PPARd knockdown. Apoptosis was significantly
increased after cells were treated with a combination of GSK0660
(0.2 mM) and ATRA compared to ATRA alone (Figure 4A).
Viability assays confirmed these results with GSK0660 on its own
slightly reducing cell viability to 88.0610.6% of the controls, but
substantially decreased viability in combination with increasing
doses of ATRA (Table 1). Transfection of SH-SY5Y cells with
PPARd or SCR siRNA decreased the overall viability of the cells,
and this was reflected in the reduced viability of the controls
(Figure 4B). However, SH-SY5Y cells transfected with PPARd
siRNA had reduced viability in response to ATRA, compared to
control SCR siRNA-treated cells (Figure 4B); in the control cells,
viability increased in response to ATRA, as is frequently observed
(see Figure S1B for example). PPARd knockdown alone had no
significant effect on apoptosis, but had a small effect of increasing
apoptosis in combination with ATRA doses of 8 mM or more
(P= 0.014; Figure 4C).
Thus, PPARd inhibition reduced viability and increased cell
death after treatment with ATRA, supporting the hypothesis that
PPARd mediates survival in ATRA-treated cells. To test this
hypothesis further, we pre-treated SH-SY5Y cells with a PPARd
agonist (0.1 mM L165-041), predicting that it would rescue cells
from death mediated by a combination of 5-LO inhibition and
ATRA. In viability experiments, the PPARd agonist did indeed
increase the IC50 of celecoxib/ATRA and MK886/ATRA
combinations, although overall survival at the highest concentra-
tions of ATRA (10–15 mM) was not affected (Table 2).
Table 2. The effect of AA-signalling agonists and antagonists on the viability of SH-SY5Y neuroblastoma cells treated with ATRA
(dose-response) in combination with fixed doses of the 5-LO inhibitors celecoxib or MK886.
Drug combined with
ATRA dose-response Agonist/antagonist (0.1 mM) Viability IC50 (mM) Lower asymptote
Celecoxib 22 mM none 4.2762.03 0.26%60.06
MK886 1 mM none 4.961.7 0.26%61.6
Celecoxib 22 mM 5-oxo-ETE 7.361.4 42.6%67.06
MK886 1 mM 5-oxo-ETE 4.960.9 22.05%66.4
Celecoxib 22 mM LTA4 6.960.7 8.8%63.1
MK886 1 mM LTA4 4.960.1 2.1%60.3
Celecoxib 22 mM L165-041 12.060.5 5.9%62.4
MK886 1 mM L165-041 8.460.4 1.2%60.2
SH-SY5Y cells were pre-treated with 0.1 mM 5-oxo-ETE, 0.1 mM LTA4 or 0.1 mM L165-041 2 h prior to treatment with 22 mM celecoxib and an ATRA dose response, or
1 mMMK886 and an ATRA dose response. Viability was measured 24 h after treatment using XTT assays. The IC50 values are for the ATRA dose-response with fixed doses
of the 5-LO inhibitors celecoxib or MK886 and in the presence of agonist/antagonist or control vehicle, and the lower asymptote reflects the viability of cells at the
highest concentrations of ATRA in the dose-response curve. For viability experiments, there were three technical replicates for each of three dose-response experiments.
Results are mean %6SEM.
doi:10.1371/journal.pone.0068859.t002
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Differential PPARd Isoform Expression Affects the Balance
Between Cell Death and Survival
Of the five different PPARd isoforms described, PPARd1 and
PPARd2 are the most widely expressed in different tissues; current
evidence suggests that PPARd2 is an inhibitory isoform lacking the
ligand binding domain, although a translation product has yet to
be identified [18]. We measured the expression of both PPARd1
and PPARd2 in neuroblastoma cells (Figure 5A) and found that
2 h after treatment with ATRA, PPARd1 expression increased
significantly with ATRA concentration but there was no
significant effect of MK886 or celecoxib on ATRA-induced
PPARd1 levels. In contrast, celecoxib or MK886 increased
PPARd2 expression in combination with ATRA (Figure 5A). To
determine the effect of PPARd2 on cell survival and apoptosis, we
created a tetracycline-inducible PPARd2 system in SH-SY5Y cells
(SH-SY5Ytet12PPARd2). In the absence of doxycycline, PPARd2
expression was higher than in the parental SH-SY5Ytet12 cells but
was significantly increased 24 and 48 h after treatment with
doxycycline (Figure 5B). Up-regulation of PPARd2 expression in
the SH-SY5Ytet12PPARd2 cells significantly increased apoptosis
after 48 h (Figure 5C). This was confirmed by cell viability assays
over the same time scale (Figure 5D). Doxycycline did not increase
apoptosis or slow growth in the SH-SY5Ytet12 cells (Figure 5C and
D). As an additional test, we transiently transfected the empty
vector (pcDNA4/TO) or the pcDNA4/TO PPARd2 construct
into SH-SY5Y cells. Using this approach, PPARd2 mRNA
expression after 48 h was lower than in the stable inducible
system (Figure 5E) and there was no baseline expression of
PPARd2 mRNA in the pcDNA4/TO controls. As with the
inducible system, cells transfected with the PPARd2 construct had
higher levels of apoptosis (Figure 5F).
PPARd Expression and Prognostic Significance in Primary
Neuroblastoma Tumours
The in vitro PPARd expression, knockdown and agonist/
antagonist studies suggest that PPARd may have a role in the
survival of tumour cells in vivo. To address this question,
microarray data from a cohort of 251 neuroblastoma primary
tumours [33] were analysed. The expression of PPARd1 and
ALOX5 were examined across the following groups: stages 1 & 2,
stage 3, stage 4, stage 4S and MYCN amplified neuroblastoma.
Low PPARd1 or ALOX5 expression was significantly associated
with MYCN amplification status (Figure 6A and B), and low
PPARd1 expression was significantly associated with poor survival
(Figure 6C). However, when multivariate analysis was carried out,
with: age at diagnosis, MYCN amplification status, stage and
PPARd1 expression, the independent contribution of PPARd1 was
not significant, suggesting that the prognostic significance of low
PPARd1 was due to its strong correlation with MYCN amplifica-
tion status.
Figure 3. PPRE activation by PPARd after RA treatment. (A) PPRE
reporter activation in SH-SY5Y cells 2 h after treatment with control
vehicle (white bar), 0.1 mM 5-oxo-ETE (light grey bar), 4 mM ATRA (dark
grey bar), or 10 mM ATRA (black bar). PPRE activation was significantly
higher with all 3 treatments compared to control (1-way ANOVA with
contrasts: P = 0.019, P = 0.01 and P.0.001 for each treatment, respec-
tively). (B) PPARd1 mRNA levels in SH-SY5Y cells transfected with 10 nM
PPARd (black bars) or SCR siRNA (grey bars) for 24 h and then treated
with control vehicle (0) or ATRA at 4 mM or 10 mM for 2 h. The SCR
control did not significantly affect PPARd1 expression, compared to the
mock-transfected control (white bar; P = 0.566). Across treatments,
PPARd siRNA significantly decreased PPARd1 mRNA expression
compared to SCR and mock-transfected controls (1-way ANOVA,
P,0.001). (C) PPRE reporter activation in siRNA-transfected SH-SY5Y
cells in the presence of ATRA (4 mM or 10 mM) or control vehicle (0).
PPARd (black bars) or SCR (grey bars) siRNA had no effect on the
controls (C; 1-way ANOVA with contrasts, P = 0.85). Reporter activation
was significantly lower in the PPARd siRNA-transfected cells after
treatment with 4 mM or 10 mM ATRA (1-way ANOVA with contrasts,
P,0.001 and P=0.015, respectively). All error bars are6SEM.
doi:10.1371/journal.pone.0068859.g003
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Discussion
AA has opposing effects on cell survival: inhibition of PLA2 is
associated with decreased survival and motility [34], but AA
release and its subsequent accumulation after treatment with
cytotoxic agents has been suggested to sensitise cells to apoptosis
[35]. Our study, alongside others [11], [12], has shown that
combining RA with celecoxib synergistically promotes cell death
of neuroblastoma cells in vitro. It is likely that inhibition of AA
metabolism by cyclooxygenases and lipooxygenases promotes cell
death by two mechanisms: firstly by preventing the synthesis of
mediators of cell survival and, secondly, by promoting an
accumulation of AA [36]. Indeed, combinations of inhibitors of
AA metabolism (celecoxib) and DNA-damaging drugs that
promote AA release, promotes cell death effectively in vitro and
in vivo [10]. It has recently been shown that activated caspase-3
from dying cells promotes AA release via PLA2 in surrounding
cells, thus promoting the regrowth of irradiated tumour cells [37],
indicating that targeting AA signalling after drug treatment may
minimise drug resistance.
We used small-molecule inhibitors targeted against cyclooxy-
genases and lipoxygenases in combination with ATRA to elucidate
whether AA metabolism promotes cell survival in neuroblastoma
cells. Previous studies suggest that PGE2 is an important mediator
of RA-induced cell survival signalling [38–40]. However, later
studies, including this study, have shown that exogenous PGE2
does not affect ATRA and celecoxib-induced cell death [11].
Results from a range of experimental approaches support a
COX2-independent mechanism for RA mediated cell survival
signalling. The FLAP inhibitor MK886, prevents 5-LO activation
and consistently reduced cell viability in combination with RA,
suggesting that LO metabolites are important mediators of cell
survival after RA treatment. This is also consistent with findings
that celecoxib is a potent inhibitor of 5-LO [29] and synergistically
promotes cell death in combination with RA. In B cells, 5-oxo-
ETE is a major product of AA metabolism which accumulates as a
result of oxidative stress. 5-oxo-ETE production is promoted
through increased AA production and also increasing levels of
NADP+, a cofactor for 5-HEDH [41]. Furthermore, 5-oxo-ETE
production is associated with cell survival after treatment with
cytotoxic agents in prostate cancer cells [42], [43]. In our study, 5-
oxo-ETE partially rescued cells from a combination of RA and
celecoxib or MK886 (summarised in Figure 7), suggesting that
lipoxygenase metabolites such as 5-oxo-ETE mediate RA-induced
cell-survival signalling. Although previous studies have suggested
that ATRA is a potent PPARd ligand [13], subsequent work has
not been able to demonstrate binding of ATRA to PPARd, PPRE-
reporter activation by 0.3 mM ATRA or increased ATRA-
mediated expression of PPARd target genes [15–17]. In this study
we found that ATRA or 5-oxo-ETE treatment activated PPARd-
mediated PPRE-reporter activity in neuroblastoma cells. In
contrast to earlier work, the concentrations of ATRA (1 mM–
Figure 4. PPARd inhibition sensitises cells to cell death after
treatment with ATRA. All graphs show data for SH-SY5Y cells. (A)
Apoptosis was measured after 24 h of treatment using flow cytometry.
Cells were treated with increasing doses of ATRA (N, solid line) or
increasing doses of ATRA in the presence of 0.2 mM GSK0660 (%,
dashed line). The interaction P-value for GSK0660 and ATRA was
P,0.001(ANOVA). Data for GSK0660 alone are in Table 1. (B) Viability
determined by XTT assay for cells transfected with PPARd (%, dashed
line) or SCR siRNA (N, solid line) and treated with increasing doses of
ATRA. (C) Apoptosis of cells transfected with PPARd (black bars) or SCR
siRNA (white bars) and treated with 0, 4 mM, 8 mM or 10 mM ATRA.
PPARd knockdown alone did not increase apoptosis; ATRA at
concentrations of 8 mM or above increased apoptosis compared to
control (no ATRA) and apoptosis at these concentrations was increased
by PPARd knockdown (Linear mixed effects model, effect of siRNA
P= 0.014). The level of apoptosis ranged from a mean of 16% in siRNA-
treated cells without ATRA to 67% in cells treated with PPARd siRNA
and 15 mM ATRA. All error bars are6SEM.
doi:10.1371/journal.pone.0068859.g004
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15 mM) we used are high and likely to induce AA release as a
result of cell stress resulting from physical effects of ATRA on
membranes.
The role of PPARd in survival responses of ATRA-treated cells
is supported by experiments with siRNA-mediated knockdown of
PPARd1 and by the PPARd antagonist that reduced cell survival
in combination with ATRA, effects also observed with celecoxib
and MK886. Furthermore, a PPARd agonist abrogated the effects
of celecoxib or 5-LO inhibition.
Figure 5. Expression of PPARd isoforms after 5-LO inhibition and treatment. (A) PPARd1 and PPARd2 (bars with diagonal lines) mRNA
expression after treatment with 0, 4 mM or 15 mM ATRA in the presence of control vehicle (no shading), 22 mM celecoxib (light grey shading) or 1 mM
MK886 (dark grey shading). PPARd1 mRNA expression increased with ATRA treatment (ANOVA, P = 0.03); PPARd2 mRNA expression increased
significantly after treatment with celecoxib with ATRA or MK886 with ATRA (ANOVA, P = 0.033). (B) Expression of PPARd2 transcripts in SH-
SY5Ytet12PPARd2 cells treated with doxycycline (referred to as PPARd2+ve cells; grey bars, diagonal lines) and without doxycycline (referred to as
PPARd2-ve cells; grey bars; no diagonal lines). Parental cells (SH-SY5Ytet12 or Tet12 in the legend) are also shown with (+ve, white bars with diagonal
lines) and without (2ve; white bars) doxycycline treatment. (C) Apoptosis determined using flow cytometry in PPARd2-ve and PPARd2+ve cells after
48 h compared to control SH-SY5Ytet12 cells with (Dox; Tet12+ve) and without (c; Tet12-ve) doxycycline. Three experiments, 2–3 replicates per
experiment; data were normalised to the mean control (without doxycycline) per experiment for each cell line. Up-regulation of PPARd2 expression
with doxycycline significantly increased apoptosis of SH-SY5Ytet12PPARd2 cells (Welch’s t test on all normalised values t13.4 = 2.3, P = 0.037), but there
was no effect on SH-SY5Ytet12 cells (t7.6 =20.14, P.0.8). Overall levels of apoptosis (not normalised) increased from a mean of 22.5% in
SY5Ytet12PPARd2 cells without doxycycline to 32.3% in cells after induction of PPARd2. Despite the leaky expression of PPARd2 in SH-SY5Ytet12PPARd2
cells without doxycycline, levels of apoptosis were not significantly higher than in the parental SH-SY5Ytet12 cells (P.0.4). (D) Viability, measured by
XTT assays for the PPARd2-ve (N, solid line) cells (no doxycycline), PPARd2+ve cells (doxycycline;%, dashed line), Tet12-ve (no doxycycline; m, solid
grey line) and Tet12+ve cells (doxycycline; D, dashed grey line) over 48 h. (E) Normalised expression of PPARd2 transcripts in SH-SY5Y cells after
transient transfection with the empty pcDNA4/TO vector (vec; white bars) or pcDNA4/TO PPARd2 (PPARd2; grey bars). Cells transfected with pcDNA4/
TO PPARd2 had significantly higher expression of PPARd2 mRNA 48 h after transfection than the control cells transfected with empty pcDNA4/TO
vector (Mann Whitney U, P.0.001). (F) Apoptosis, shown normalised to the mean vector control in each of three experiments (3–5 replicates per
experiment) in SH-SY5Y cells 72 h after transient transfection with the empty pcDNA4/TO vector (vec; white bars) or pcDNA4/TO PPARd2 (PPARd2;
grey bars).Mean apoptosis (38.8%) in cells transfected with pcDNA4/TO PPARd2 was significantly higher than the vector-transfected controls (13.8%;
t-test, P,0.05). All error bars are6SEM.
doi:10.1371/journal.pone.0068859.g005
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PPARd performs a complex role co-ordinating the activity of
other PPARs via ligand-independent transcriptional repression at
PPREs [44]. Since we found consistent increases in reporter
activity after treatment with ATRA or 5-oxo-ETE, which
decreased after 5-LO inhibition, this suggests that, at least in
part, cell survival signals rely on ligand activation of PPARd1.
Additionally, the putative dominant-negative isoform, PPARd2,
was markedly induced at the mRNA level after celecoxib/ATRA
treatment. A dominant-negative role for PPARd2 was also
supported by the finding that ectopic PPARd2 expression
increased apoptosis and reduced proliferation of neuroblastoma
cells. In our model, the effects of PPARd2 were observed after
72 h, and this is not consistent with the levels of cell death
observed after 24 h with the drug combinations. However,
PPARd2 up-regulation may function to prolong the suppression
of PPARd1-mediated cell survival and growth signalling. We also
speculate that since 5-LO inhibitors induced PPARd2, PPARd2
might be repressed in a ligand-dependent manner by PPARd1.
Understanding the balance of cell-survival and cell-death
signalling pathways in vivo will help determine the reasons for
treatment failure and optimise therapeutic strategies with RA in
neuroblastoma patients. Low PPARd and ALOX5 expression was
associated with MYCN amplification in a cohort of 251 primary
neuroblastoma tumours. Although low PPARd1 expression was
significantly associated with poor prognosis, it was not an
independent prognostic indicator due the correlation with MYCN
amplification. It is possible that PPARd1 expression is up-
regulated in tumour cells in response to patient treatment and
this remains to be investigated. It should also be noted that MYCN
expression is down regulated in neuroblastoma cells after
treatment with RA [2], so if PPARd1 expression is repressed
directly or indirectly by MYCN, its potential up-regulation in
response to RA would act as a compensatory cell-survival and cell-
growth mechanism.
The mechanism linking low PPARd1 and ALOX5 to MYCN
amplification status in neuroblastoma needs to be investigated, and
the study raises questions over the potential role of PPARd1 in
promoting cell survival signalling in neuroblastoma (Figure 7).
Clearly, if these ideas are supported by future work, this will lead
to new targets for increasing the efficiency of RA, particularly
PPARd and the enzymes involved AA metabolism. Celecoxib also
promotes death of neuroblastoma cells synergistically in combi-
nation with cytotoxic drugs in vitro and in vivo [10], therefore it is
important to determine if PPARd signalling is a common
mechanism of drug resistance in cancer.
In summary, the results of this study in neuroblastoma cells
suggest that high levels of ATRA induce a survival response
mediated by the metabolism of AA by lipoxygenases, particularly
5-LO. The experimental data implicate the 5-LO product 5-oxo-
ETE as a ligand activating PPARd1 to promote survival. Blocking
this signalling pathway at the level of AA release, 5-LO-mediated
metabolism or PPARd1 antagonism promoted cell death.
Furthermore, ligand-dependent and ligand-independent- negative
feedback relationships between PPARd1 and a dominant-negative
PPARd isoform, PPARd2 may have a role in the control of
survival signalling. It will be important to test these ideas using
Figure 6. Clinical data from a cohort of 251 primary neuroblastomas. Expression of (A) PPARd1 mRNA and (B) ALOX5 (5-LO) mRNA in stages
1–4, 4S and MYCN amplified (Amp) groups. (C) Kaplan-Meier survival analysis for 251 primary neuroblastomas based on PPARd1 mRNA expression.
Low PPARd1 or ALOX5 expression was significantly associated with MYCN amplification status (Wilcoxon test; P,0.001 for both). For Kaplan-Meier
analysis of patient survival, a cut-off at the first quartile was used to distinguish between low PPARd1 and high PPARd1 expression: low PPARd1
expression defined in this way was significantly associated with poor survival (Log Rank test, P,0.001). Multivariate analysis with: age at diagnosis,
MYCN amplification status, stage and PPARd1 expression showed that PPARd1 expression did not contribute significantly (P = 0.866). Box and whisker
plots show the median (horizontal line), 25th and 75th percentiles (box horizontal boundaries), with the whiskers above and below extending to the
most extreme data point.1.5 times the interquartile range from the box. Outliers are shown as circles.
doi:10.1371/journal.pone.0068859.g006
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other cytotoxic drugs which promote AA release and in other cell
types. Finally, the possibility of a more-general role in cell survival
for PPARd1 with negative-feedback regulation by a dominant-
negative isoform needs further investigation.
Supporting Information
Figure S1 The role of COX2 in retinoic acid mediated
cell death.
(TIF)
Figure S2 PPARd expression and PPRE activation in SH-
SY5Y cells.
(TIF)
Figure S3 Western blot for cleaved caspase-3.
(TIF)
Figure S4 Western blot for COX2.
(TIF)
Table S1 Viability of NB69 and NGP neuroblastoma
cells in response to ATRA in combination with celecoxib,
or inhibitors of PLA2 and 5-LO.
(DOCX)
Table S2 Viability of NB69, NGP and SH-SY5Y neuro-
blastoma cells in response to ATRA in combination with
the dual COX1 and COX2 inhibitor diclofenac, or
inhibitors of 12-LO and 15-LO.
(DOCX)
Text S1 The role of COX2 in cell survival.
(DOCX)
Text S2 12-LO and 15-LO inhibitors in combination
with ATRA.
(DOCX)
Acknowledgments
We would like to thank Pfizer for providing the celecoxib.
Author Contributions
Data acquisition: EB FP CW HT FW. Conception and design of the work:
EB CR. Analysis and interpretation of data: EB CR FW. Manuscript
preparation: EB CR. Manuscript revision and final approval: EB FP CW
HT FW CR.
References
1. Soprano DR, Qin P, Soprano KJ (2004) Retinoic acid receptors and cancers.
Annu Rev Nutr 24: 201–221.
2. Thiele CJ, Reynolds CP, Israel MA (1985) Decreased expression of N-myc
precedes retinoic acid-induced morphological differentiation of human neuro-
blastoma. Nature 313: 404–406.
3. Sidell N, Altman A, Haussler MR, Seeger RC (1983) Effects of retinoic acid (RA)
on the growth and phenotypic expression of several human neuroblastoma cell
lines. Exp Cell Res 148: 21–30.
4. Verma AK, Conrad EA, Boutwell RK (1982) Differential effects of retinoic acid
and 7,8-benzoflavone on the induction of mouse skin tumors by the complete
carcinogenesis process and by the initiation-promotion regimen. Cancer Res 42:
3519–3525.
5. Noy N (2010) Between death and survival: retinoic acid in regulation of
apoptosis. Annu Rev Nutr 30: 201–217.
6. Farooqui AA, Horrocks LA (2005) Signaling and interplay mediated by
phospholipases A2, C, and D in LA-N-1 cell nuclei. Reprod Nutr Dev 45: 613–
631.
7. Antony P, Freysz L, Horrocks LA, Farooqui AA (2003) Ca2+-independent
phospholipases A2 and production of arachidonic acid in nuclei of LA-N-1 cell
cultures: a specific receptor activation mediated with retinoic acid. Brain Res
Mol Brain Res 115: 187–195.
8. Levine L (2001) Stimulated release of arachidonic acid by agonists of the
peroxisome proliferator-activated receptor and retinoic acid receptors. Prosta-
glandins Leukot Essent Fatty Acids 65: 229–232.
9. Levine L (2003) Tamoxifen stimulates arachidonic acid release from rat liver
cells by an estrogen receptor-independent, non-genomic mechanism. BMC
Cancer 3: 24.
10. Ponthan F, Wickstrom M, Gleissman H, Fuskevag OM, Segerstrom L, et al.
(2007) Celecoxib prevents neuroblastoma tumor development and potentiates
the effect of chemotherapeutic drugs in vitro and in vivo. Clin Cancer Res 13:
1036–1044.
11. Liu JP, Wei HB, Zheng ZH, Guo WP, Fang JF (2010) Celecoxib increases
retinoid sensitivity in human colon cancer cell lines. Cell Mol Biol Lett 15: 440–
450.
12. Redova M, Chlapek P, Loja T, Zitterbart K, Hermanova M, et al. (2010)
Influence of LOX/COX inhibitors on cell differentiation induced by all-trans
retinoic acid in neuroblastoma cell lines. Int J Mol Med 25: 271–280.
Figure 7. Model of ATRA-stimulated cell-survival signalling in
neuroblastoma. (A) ATRA cell-survival signalling is proposed to be
mediated through PLA2-dependent AA release and metabolism to
lipoxygenase products such as 5-oxo-ETE, which activate PPARd1 to
promote expression of survival genes. We suggest that the expression
of inhibitory PPARd2 transcripts is suppressed when this pathway is
activated. (B) When the PLA2/5-LO/PPARd pathway is inhibited, we
propose that the expression of genes facilitating cell survival is
prevented, a process facilitated by up-regulation of PPARd2 and
PPARd2-mediated suppression, allowing the expression of either stress-
induced or RAR-induced (or both) death genes to predominate and
drive cell death.
doi:10.1371/journal.pone.0068859.g007
PPARd Signalling in Neuroblastoma
PLOS ONE | www.plosone.org 10 July 2013 | Volume 8 | Issue 7 | e68859
13. Shaw N, Elholm M, Noy N (2003) Retinoic acid is a high affinity selective ligand
for the peroxisome proliferator-activated receptor beta/delta. J Biol Chem 278:
41589–41592.
14. Schug TT, Berry DC, Shaw NS, Travis SN, Noy N (2007) Opposing effects of
retinoic acid on cell growth result from alternate activation of two different
nuclear receptors. Cell 129: 723–733.
15. Rieck M, Meissner W, Ries S, Muller-Brusselbach S, Muller R (2008) Ligand-
mediated regulation of peroxisome proliferator-activated receptor (PPAR) beta/
delta: a comparative analysis of PPAR-selective agonists and all-trans retinoic
acid. Mol Pharmacol 74: 1269–1277.
16. Borland MG, Foreman JE, Girroir EE, Zolfaghari R, Sharma AK, et al. (2008)
Ligand activation of peroxisome proliferator-activated receptor-beta/delta
inhibits cell proliferation in human HaCaT keratinocytes. Mol Pharmacol 74:
1429–1442.
17. Borland MG, Khozoie C, Albrecht PP, Zhu B, Lee C, et al. (2011) Stable over-
expression of PPARbeta/delta and PPARgamma to examine receptor signaling
in human HaCaT keratinocytes. Cell Signal 23: 2039–2050.
18. Lundell K, Thulin P, Hamsten A, Ehrenborg E (2007) Alternative splicing of
human peroxisome proliferator-activated receptor delta (PPAR delta): effects on
translation efficiency and trans-activation ability. BMC Mol Biol 8: 70.
19. Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS (1978) Multiple
neurotransmitter synthesis by human neuroblastoma cell lines and clones.
Cancer Res 38: 3751–3757.
20. Brodeur GM, Sekhon G, Goldstein MN (1977) Chromosomal aberrations in
human neuroblastomas. Cancer 40: 2256–2263.
21. Feder MK, Gilbert F (1983) Clonal evolution in a human neuroblastoma. J Natl
Cancer Inst 70: 1051–1056.
22. Lovat PE, Oliverio S, Ranalli M, Corazzari M, Rodolfo C, et al. (2002)
GADD153 and 12-lipoxygenase mediate fenretinide-induced apoptosis of
neuroblastoma. Cancer Res 62: 5158–5167.
23. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, et al. (1988)
Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug
sensitivity in culture using human and other tumor cell lines. Cancer Res 48:
4827–4833.
24. Pinheiro J, Bates D., DebRoy D., Sarkar D., R Core Team (2008) nmle: Linear
and non-linear mixed effects models. R-package version 31–89.
25. R Development Core Team (2008) R: A Language and environment for
statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
ISBN 3–900051–07–0, URL http://www.R-project.org.
26. Lovat PE, Ranalli M, Corazzari M, Raffaghello L, Pearson AD, et al. (2003)
Mechanisms of free-radical induction in relation to fenretinide-induced
apoptosis of neuroblastoma. J Cell Biochem 89: 698–708.
27. Funk CD (2001) Prostaglandins and leukotrienes: advances in eicosanoid
biology. Science 294: 1871–1875.
28. Samuelsson B (1983) Leukotrienes: mediators of immediate hypersensitivity
reactions and inflammation. Science 220: 568–575.
29. Maier TJ, Tausch L, Hoernig M, Coste O, Schmidt R, et al. (2008) Celecoxib
inhibits 5-lipoxygenase. Biochem Pharmacol 76: 862–872.
30. Sveinbjornsson B, Rasmuson A, Baryawno N, Wan M, Pettersen I, et al. (2008)
Expression of enzymes and receptors of the leukotriene pathway in human
neuroblastoma promotes tumor survival and provides a target for therapy.
FASEB J 22: 3525–3536.
31. Dixon RA, Diehl RE, Opas E, Rands E, Vickers PJ, et al. (1990) Requirement of
a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 343: 282–
284.
32. Powell WS, Gravelle F, Gravel S (1992) Metabolism of 5(S)-hydroxy-6,8,11,14-
eicosatetraenoic acid and other 5(S)-hydroxyeicosanoids by a specific dehydro-
genase in human polymorphonuclear leukocytes. J Biol Chem 267: 19233–
19241.
33. Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, et al. (2006)
Customized oligonucleotide microarray gene expression-based classification of
neuroblastoma patients outperforms current clinical risk stratification. J Clin
Oncol 24: 5070–5078.
34. Patel MI, Singh J, Niknami M, Kurek C, Yao M, et al. (2008) Cytosolic
phospholipase A2-alpha: a potential therapeutic target for prostate cancer. Clin
Cancer Res 14: 8070–8079.
35. Levine L (2003) Does the release of arachidonic acid from cells play a role in
cancer chemoprevention? FASEB J 17: 800–802.
36. Chen KC, Chang LS (2009) Arachidonic acid-induced apoptosis of human
neuroblastoma SK-N-SH cells is mediated through mitochondrial alteration
elicited by ROS and Ca(2+)-evoked activation of p38alpha MAPK and JNK1.
Toxicology 262: 199–206.
37. Huang Q, Li F, Liu X, Li W, Shi W, et al. (2011) Caspase 3-mediated
stimulation of tumor cell repopulation during cancer radiotherapy. Nat Med 17:
860–866.
38. Lee EO, Shin YJ, Chong YH (2004) Mechanisms involved in prostaglandin E2-
mediated neuroprotection against TNF-alpha: possible involvement of multiple
signal transduction and beta-catenin/T-cell factor. J Neuroimmunol 155: 21–31.
39. Sugino Y, Misawa A, Inoue J, Kitagawa M, Hosoi H, et al. (2007) Epigenetic
silencing of prostaglandin E receptor 2 (PTGER2) is associated with progression
of neuroblastomas. Oncogene 26: 7401–7413.
40. Alique M, Herrero JF, Lucio-Cazana FJ (2007) All-trans retinoic acid induces
COX-2 and prostaglandin E2 synthesis in SH-SY5Y human neuroblastoma
cells: involvement of retinoic acid receptors and extracellular-regulated kinase 1/
2. J Neuroinflammation 4: 1.
41. Grant GE, Gravel S, Guay J, Patel P, Mazer BD, et al. (2011) 5-oxo-ETE is a
major oxidative stress-induced arachidonate metabolite in B lymphocytes. Free
Radic Biol Med 50: 1297–1304.
42. O’Flaherty JT, Rogers LC, Paumi CM, Hantgan RR, Thomas LR, et al. (2005)
5-Oxo-ETE analogs and the proliferation of cancer cells. Biochim Biophys Acta
1736: 228–236.
43. Ghosh J (2004) Rapid induction of apoptosis in prostate cancer cells by selenium:
reversal by metabolites of arachidonate 5-lipoxygenase. Biochem Biophys Res
Commun 315: 624–635.
44. Shi Y, Hon M, Evans RM (2002) The peroxisome proliferator-activated
receptor delta, an integrator of transcriptional repression and nuclear receptor
signaling. Proc Natl Acad Sci U S A 99: 2613–2618.
PPARd Signalling in Neuroblastoma
PLOS ONE | www.plosone.org 11 July 2013 | Volume 8 | Issue 7 | e68859
